Compare Stocks: VRDN, PTGX, IBRX, and TGTX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$8.83 +3.6%	$7.88	$1.95 ▼ $12.43	$9.03B	0.04	9.96 million shs	8.35 million shs
PTGX Protagonist Therapeutics	$140.97 -1.0%	$144.91	$62.24 ▼ $160.81	$9.22B	1.8	660,881 shs	508,012 shs
TGTX TG Therapeutics	$56.19	$53.72	$26.76 ▼ $59.30	$8.60B	1.67	1.79 million shs	1.61 million shs
VRDN Viridian Therapeutics	$20.00 -2.8%	$22.01	$13.18 ▼ $34.29	$2.33B	0.97	1.63 million shs	1.23 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	+0.83%	+0.71%	+5.71%	-2.85%	+235.04%
PTGX Protagonist Therapeutics	+0.41%	-1.75%	-1.31%	+16.20%	+111.27%
TGTX TG Therapeutics	-2.16%	-1.70%	+4.19%	+2.28%	+58.28%
VRDN Viridian Therapeutics	+0.49%	-4.77%	-10.88%	+11.98%	+1.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$8.83 +3.6%	$7.88	$1.95 ▼ $12.43	$9.03B	0.04	9.96 million shs	8.35 million shs
PTGX Protagonist Therapeutics	$140.97 -1.0%	$144.91	$62.24 ▼ $160.81	$9.22B	1.8	660,881 shs	508,012 shs
TGTX TG Therapeutics	$56.19	$53.72	$26.76 ▼ $59.30	$8.60B	1.67	1.79 million shs	1.61 million shs
VRDN Viridian Therapeutics	$20.00 -2.8%	$22.01	$13.18 ▼ $34.29	$2.33B	0.97	1.63 million shs	1.23 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	+0.83%	+0.71%	+5.71%	-2.85%	+235.04%
PTGX Protagonist Therapeutics	+0.41%	-1.75%	-1.31%	+16.20%	+111.27%
TGTX TG Therapeutics	-2.16%	-1.70%	+4.19%	+2.28%	+58.28%
VRDN Viridian Therapeutics	+0.49%	-4.77%	-10.88%	+11.98%	+1.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	2.86	Moderate Buy	$14.20	60.82% Upside
PTGX Protagonist Therapeutics	2.89	Moderate Buy	$147.13	4.37% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	12.12% Upside
VRDN Viridian Therapeutics	2.85	Moderate Buy	$38.69	93.46% Upside

Current Analyst Ratings Breakdown

Latest VRDN, PTGX, IBRX, and TGTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	IBRX ImmunityBio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	VRDN Viridian Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$36.00 ➝ $38.00
9/21/2026	TGTX TG Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C+) ➝ Buy (B-)
9/14/2026	VRDN Viridian Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/7/2026	TGTX TG Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
9/1/2026	PTGX Protagonist Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$153.00 ➝ $180.00
9/1/2026	PTGX Protagonist Therapeutics	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$178.00 ➝ $190.00
9/1/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$175.00 ➝ $182.00
8/31/2026	PTGX Protagonist Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/31/2026	PTGX Protagonist Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$113.29M	82.61	N/A	N/A	($0.51) per share	-17.31
PTGX Protagonist Therapeutics	$281.99M	32.35	N/A	N/A	$9.83 per share	14.34
TGTX TG Therapeutics	$799.54M	10.76	$2.80 per share	20.05	$4.08 per share	13.77
VRDN Viridian Therapeutics	$70.85M	31.98	N/A	N/A	$6.18 per share	3.24

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)
PTGX Protagonist Therapeutics	-$130.15M	$1.03	136.87	N/A	N/A	29.40%	12.03%	11.23%	11/5/2026 (Estimated)
TGTX TG Therapeutics	$447.18M	$2.74	20.51	21.20	2.41	55.22%	73.49%	34.14%	11/2/2026 (Estimated)
VRDN Viridian Therapeutics	-$342.60M	-$3.37	N/A	N/A	N/A	-505.86%	-72.97%	-42.80%	11/4/2026 (Estimated)

Latest VRDN, PTGX, IBRX, and TGTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	VRDN Viridian Therapeutics	-$1.03	-$1.05	-$0.02	-$1.05	$0.06 million	$0.28 million
8/5/2026	Q2 2026	PTGX Protagonist Therapeutics	$2.27	$2.29	+$0.02	$2.29	$212.03 million	$213.48 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
PTGX Protagonist Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A
VRDN Viridian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	5.72	5.70
PTGX Protagonist Therapeutics	N/A	21.71	21.71
TGTX TG Therapeutics	1.23	4.27	3.72
VRDN Viridian Therapeutics	0.43	16.95	16.95

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
PTGX Protagonist Therapeutics	98.63%
TGTX TG Therapeutics	58.58%
VRDN Viridian Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	66.10%
PTGX Protagonist Therapeutics	5.19%
TGTX TG Therapeutics	8.87%
VRDN Viridian Therapeutics	2.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	691	1.06 billion	359.28 million	Optionable
PTGX Protagonist Therapeutics	141	64.71 million	61.35 million	Optionable
TGTX TG Therapeutics	399	153.07 million	139.49 million	Optionable
VRDN Viridian Therapeutics	252	113.29 million	110.57 million	Optionable

VRDN, PTGX, IBRX, and TGTX Headlines

Recent News About These Companies

Viridian Therapeutics (NASDAQ:VRDN) Upgraded to Sell at Wall Street Zen

September 26 at 1:24 AM | americanbankingnews.com

Wall Street Zen Upgrades Viridian Therapeutics (NASDAQ:VRDN) to "Sell"

September 26 at 1:23 AM | marketbeat.com

Bank of America Corp DE Makes New $17.35 Million Investment in Viridian Therapeutics, Inc. $VRDN

September 25, 2026 | marketbeat.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)

September 23, 2026 | theglobeandmail.com

Viridian Therapeutics' Lumvoa Off to 'Stronger Start' Than Anticipated, RBC Says

September 22, 2026 | finance.yahoo.com

Viridian Therapeutics: Two Products, One Commercial Buildout

September 17, 2026 | seekingalpha.com

Squarepoint Ops LLC Purchases 133,046 Shares of Viridian Therapeutics, Inc. $VRDN

September 13, 2026 | marketbeat.com

Viridian Intersects Over 50 Metres of Mineralization from Surface at Kraken Main

September 8, 2026 | globenewswire.com

Legal & General Group Plc Takes Position in Viridian Therapeutics, Inc. $VRDN

September 8, 2026 | marketbeat.com

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 5, 2026 | marketbeat.com

268,060 Shares in Viridian Therapeutics, Inc. $VRDN Acquired by Bank of New York Mellon Corp

September 5, 2026 | marketbeat.com

Wellington Management Group LLP Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

September 4, 2026 | marketbeat.com

Velan Capital Investment Management LP Has $184,000 Stock Holdings in Viridian Therapeutics, Inc. $VRDN

September 3, 2026 | marketbeat.com

Viridian Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference

September 2, 2026 | finance.yahoo.com

The Manufacturers Life Insurance Company Takes $3.31 Million Position in Viridian Therapeutics, Inc. $VRDN

September 2, 2026 | marketbeat.com

Yiheng Capital Management L.P. Has $7.36 Million Holdings in Viridian Therapeutics, Inc. $VRDN

August 31, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH) and Viridian Therapeutics (VRDN)

August 26, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Health Catalyst (HCAT) and Viridian Therapeutics (VRDN)

August 21, 2026 | theglobeandmail.com

Insider Selling: Viridian Therapeutics (NASDAQ:VRDN) Insider Sells 14,212 Shares

August 21, 2026 | insidertrades.com

Viridian Therapeutics Inc VRDN

August 15, 2026 | morningstar.comM

Viridian Therapeutics (VRDN) Receives a Buy from LifeSci Capital

August 8, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, PTGX, IBRX, and TGTX Company Descriptions

ImmunityBio NASDAQ:IBRX

$8.83 +0.31 (+3.64%)

Closing price 04:00 PM Eastern

Extended Trading

$8.87 +0.04 (+0.49%)

As of 07:58 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Protagonist Therapeutics NASDAQ:PTGX

$140.97 -1.47 (-1.03%)

Closing price 04:00 PM Eastern

Extended Trading

$141.54 +0.56 (+0.40%)

As of 07:30 PM Eastern

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

TG Therapeutics NASDAQ:TGTX

$56.19 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$55.93 -0.26 (-0.46%)

As of 07:38 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

Viridian Therapeutics NASDAQ:VRDN

$20.00 -0.57 (-2.77%)

Closing price 04:00 PM Eastern

Extended Trading

$19.99 -0.01 (-0.05%)

As of 07:30 PM Eastern

Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRDN, PTGX, IBRX, and TGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRDN, PTGX, IBRX, and TGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRDN, PTGX, IBRX, and TGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, PTGX, IBRX, and TGTX Company Descriptions

ImmunityBio NASDAQ:IBRX

Protagonist Therapeutics NASDAQ:PTGX

TG Therapeutics NASDAQ:TGTX

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VRDN, PTGX, IBRX, and TGTX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VRDN, PTGX, IBRX, and TGTX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VRDN, PTGX, IBRX, and TGTX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN, PTGX, IBRX, and TGTX Company Descriptions

ImmunityBio NASDAQ:IBRX

Protagonist Therapeutics NASDAQ:PTGX

TG Therapeutics NASDAQ:TGTX

Viridian Therapeutics NASDAQ:VRDN

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools